G1 Therapeutics' GAAP loss for 6 months of 2023 was $18.885 billion, down 4.7 times from $88.638 billion in the prior year. Revenue increased 3.2 times to $55.338 million compared to $17.475 million a year earlier.

G1 Therapeutics' GAAP loss for 3 months of 2023 was $27.595 million, down 43.9% from $49.192 million in the prior year. Revenue increased 87.6% to $12.946 million from $6.902 million a year earlier.

G1 Therapeutics' GAAP loss for 2022 was $147.56 million, down 0.5% from $148.35 million in the previous year. Revenue increased 63% to $51.301 million from $31.476 million a year earlier.

G1 Therapeutics' GAAP loss for 9 months of 2022 was $113.91 million, up 5.2% from $108.33 million in the prior year. Revenue increased 59.9% to $41.051 million from $25.68 million a year earlier.